Nephroapp
Exam Cases MCQ Bank

Search

Find tools, topics, and resources

Welcome to Nephroapp
Sign in to keep your progress and bookmarks.
Log in Create account
Explore
Exam cases MCQ Bank Topics Plans and pricing
App
Explore NephroApp
Exam Cases MCQ Bank

Study

Exam cases
MCQ Bank
Fast Recaps
Plans and pricing
‹ Fast Recaps

🫀 Transplant

19 Fast Recaps

💧 Peritoneal Dialysis ⚡ Electrolytes & Acid–Base 🩸 Hemodialysis & Access 🏥 CRRT / ICU 💓 Hypertension 🔬 Glomerular 🪨 Tubular & Stones 🦴 CKD & Bone-Mineral ⭐ Special Topics 🚨 Acute Kidney Injury
Antibody-mediated rejection (ABMR/AMR, Banff) Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step BK virus nephropathy Living donor evaluation / complications Delayed graft function / day-1 oliguria Calcineurin inhibitor toxicity CMV infection in transplant Commercial transplant abroad — returning with graft dysfunction Transplant tourism / Declaration of Istanbul T-cell mediated (cellular) rejection Immunosuppression protocols / induction Pre-transplant recipient evaluation / candidacy work-up Post-transplant lymphoproliferative disease (PTLD) Early post-transplant surgical complications (urine leak) Suspected transplant rejection without biopsy access — empirical approach ADPKD after transplant: rising creatinine and proteinuria Pregnancy after kidney transplantation Recurrent glomerular disease after kidney transplantation Transplant immunosuppression problems: tacrolimus levels, belatacept, leukopenia
6

Antibody-mediated rejection (ABMR/AMR, Banff)

Open the full topic →
Fast Recap · 7 stops

Antibody-mediated rejection at a glance

DSA inflames graft microvessels. Prove it with the Banff triad, treat in order, and call the regimen a centre protocol, not RCT-proven.

  1. DSA Pathogenesis DSA binds endothelium; complement inflames microvessels.
  2. injury C4d DSA Banff triad Injury + antibody interaction + DSA.
  3. DSA IVIG PLEX IVIG after each Plasma exchange and IVIG IVIG after each exchange; centre protocol.
  1. 1

    Stop 1 · Assessment

    Initial assessment and differential diagnosis

    Stabilise first; timing narrows the differential.

    8 h Cr

    Urgent dialysis indications

    Anuria, or high Cr with hyperkalaemia or overload (e.g. Cr 400): urgent dialysis alongside work-up.

    Key history

    Immunosuppression, adherence, CNI trough, infections, time since transplant, commercial transplant.

    First hours to days

    Early graft dysfunction

    Hyperacute rejection, vascular thrombosis, ischaemia-reperfusion / ATN, primary non-function, surgical (obstruction, leak, collection).

    Months later

    Later graft dysfunction

    ABMR, TCMR, mixed, BK nephropathy, CMV, CNI toxicity, recurrent/de novo GN.

    Doppler before biopsy: obstruction, collection, leak, TRAS (1–7% of post-transplant HTN), thrombosis. Also CNI-related TMA.

    Memory hook

    “Hours: clot or hyperacute. Months: rejection, BK or CNI.” Within 8 h: surgical emergency.

    Exam trap

    Commercial transplant, donor unknown: do NOT say “donor-specific antibody”. Report antibody screen generally; biopsy when safe; work up BK, CMV, ABMR, TCMR.

  2. 2

    Stop 2 · Investigations

    Diagnostic work-up

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Banff criteria
  2. Banff categories and differential diagnosis
  3. Treatment of active ABMR
  4. Refractory and chronic active ABMR
  5. Desensitisation
See the plans →
6

Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step

Open the full topic →
Fast Recap · 7 stops

Graft dysfunction at a glance

AKI in a single kidney on immunosuppression. Stabilise, rank by time, exclude reversible causes, then biopsy.

  1. Stabilise first Dialyse if needed; keep immunosuppression on.
  2. Time ranks causes Hours, week 1, 12 weeks, later.
  3. pre renal post Sort the compartments Exclude volume, obstruction, high trough.
  4. Biopsy, then treat Treat the biopsy, not the creatinine.
1 Stabilisation 2 Time since transplant 3 DGF 4 Pre- and post-renal 5 Renal causes and biopsy 6 Rejection 7 Infection and late
  1. 1

    Stop 1 · Emergency

    Initial assessment and stabilisation

    Treat the life threats; keep immunosuppression running.

    K⁺ keep IS
    • Hyperkalaemia, acidosis, overload, uraemia: urgent dialysis
    • Gentle ultrafiltration, never aggressive
    • Continue immunosuppression
    History

    Adherence, missed doses, new interacting drugs, diarrhoea, fever, urine output, donor and induction.

    Examination

    Volume, graft tenderness, wound, drain, Foley.

    Memory hook

    “Some Fluid Drains Through Plastic Bags”

    Sstabilise FFoley + fluids DDoppler Ttrough PPCR + DSA Bbiopsy
  2. 2

    Stop 2 · Differential

    Differential diagnosis by time since transplant

    The clock ranks the causes before any test.

    8 h wk 1 12 wk 3–12 mo >1 yr
    Within 8 hours
    Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion.
    Doppler now; absent flow = re-exploration.
    Week 1
    ATN/DGF (commonest), accelerated rejection, obstruction or leak, thrombosis, volume contraction.
    Up to 12 weeks
    Acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrence (FSGS in the first month).
    3–12 months
    BK nephropathy (peak 3–6 months), TCMR, CMV, TRAS, lymphocele.
    Over 1 year
    Non-adherence, de novo DSA → chronic active ABMR; chronic CNI toxicity, recurrent GN, TRAS, PTLD.
    Memory hook

    TCMR: usually after week 1, most often within 3–6 months.

  3. 3

    Stop 3 · Early graft

    Day-1 oliguria and delayed graft function

    Foley, fluids, Doppler; only then presumed ATN.

    Day 1 72 h 1–2 weeks
    1. 1 · Flush the Foley

      Blocked or kinked catheter first.

    2. 2 · Fluid challenge

      Reassess volume status.

    3. 3 · Renal Doppler

      Thrombosis, obstruction or leak: urgent re-exploration or urologic intervention.

    Artery thrombosis

    0.1–2%, within 72 h, painless anuria.
    Vein: haematuria, oliguria, pain, no venous flow.

    Definitions

    DGF: dialysis within the first week.
    Slow graft function: creatinine >3 mg/dL (~265 µmol/L), no dialysis.

    Presumed ATN

    Continue immunosuppression, check trough, dialysis as needed; no aggressive UF.
    Furosemide 100–200 mg only if hypervolaemic.

    Rising or beyond 1–2 weeks

    Biopsy for rejection on ATN (most centres 7–10 days); send CMV PCR.

    Exam trap

    Stopping immunosuppression for DGF or dialysis: continue it.

  4. 4

    Stop 4 · Exclusion

    Pre-renal and post-renal causes

    Exclude dehydration, obstruction and a high CNI level first.

    TRAS 1–3 wk Foley
    Pre-renal
    • Hypovolaemia, sepsis: crystalloid (preferred to albumin), stop nephrotoxins.
    • High trough: CNI vasoconstriction; find the CYP3A4 inhibitor, reduce.
    • TRAS (1–23%, first year): Doppler → MRI → angioplasty ± stent.

    Normal RI with falling urine output: haemodynamic cause.

    Post-renal
    • Blocked or kinked Foley: flush.
    • Ureteral obstruction (2–10%, within 3 months): ischaemic stricture commonest.
    • Significant hydronephrosis: nephrostomy or stent → surgical reconstruction.

    Perigraft collections

    Urine leak
    Fluid creatinine well above serum; first 3 months. Foley at once, drain, stent + Foley 1–3 weeks; cystogram before catheter out. Fails: nephrostomy, reimplant.
    Lymphocele
    Creatinine like serum; weeks to months; commoner with mTOR inhibitors. Drain if it compresses.
    Haematoma
    Early or after biopsy; usually resolves.
    Abscess
    Fever, CRP, positive culture: drain + antibiotics.
    Exam trap

    Mild hydronephrosis is often non-significant: the graft ureter has no valve; renogram first.

  5. 5

    Stop 5 · Diagnosis

    Renal causes and allograft biopsy

    Persistent unexplained rise: biopsy before treating rejection (KDIGO 9.1, 6.1).

    >100 platelets C4d SV40
    • Tacrolimus trough
    • Urinalysis, culture, protein
    • Plasma BK and CMV PCR
    • DSA (anti-HLA screen if donor unknown)
    • TMA screen: platelets, LDH, haptoglobin, film
    Doppler Resistive index
    ~0.6 normal, >0.7 high; rejection, ATN, thrombosis, hydronephrosis all raise it.
    Tacrolimus Trough
    High: toxicity likely. Low: missed doses or interaction, rejection risk.
    Typical targets: month 1 10–15, to ~6 months 8–12, later 6–8 (centre-dependent). True trough 12 ± 2 h post-dose.
    Plasma PCR BK virus
    >1,000 copies/mL beyond 2 weeks: probable.
    >10,000: presumptive BK nephropathy.
    Banff biopsy Lesions
    TCMR IA/IB: tubulitis + interstitial inflammation; intimal arteritis IIA/IIB; transmural III.
    Active ABMR: g+ptc + C4d, or g+ptc ≥2 + DSA; cg >0: chronic active.
    BK: SV40-positive inclusions. CNI: isometric vacuolisation; arteriolar hyalinosis, striped fibrosis.

    Biopsy safety: platelets >100, PT and APTT <1.2 × control, BP <140/90, sterile urine.
    Unsafe: correct first, or empirical pulse steroid if rejection likely.

    Exam trap

    High resistive index ≠ rejection: ATN, thrombosis and hydronephrosis raise it too.

  6. 6

    Stop 6 · Treatment

    Treatment of acute rejection

    Treat the biopsy, not the creatinine; grade decides.

    MP 3–5 d rATG 7–14 d S → A → R
    1. TCMR borderline with dysfunction, IA/IB

      Methylprednisolone 3–5 mg/kg (250–500 mg) IV × 3–5 days; optimise trough and adherence; add MMF (Rec 6.5).

    2. TCMR IIA–III or steroid-resistant

      rATG 1–1.5 mg/kg × 7–14 days; IIA–III: start with pulse steroid + rATG.
      After ATG: CMV and PJP prophylaxis, BK plasma PCR monitoring.

    3. Active ABMR

      PLEX 2–5 + IVIG 100–200 mg/kg after each + pulse steroid.

      Refractory, tertiary only: rituximab 375 mg/m² (RCT n=38 negative) or bortezomib 1.3 mg/m² × 4 (BORTEJECT negative).

    Mixed: TCMR by grade + PLEX, IVIG, consider rituximab.
    Chronic active ABMR: optimise tacrolimus, MMF, adherence; no proven reversal.
    No response: repeat biopsy.

    No biopsy possible

    E.g. platelets 20: methylprednisolone 500 mg × 3; correct platelets.
    ~60–70% respond within 5 days; no response: urgent biopsy or transfer.

    Unknown donor

    Anti-HLA antibody screen, not DSA; C4d substitutes on biopsy.
    Screen HBV, HCV, HIV, TB.

    Memory hook

    TCMR = S-A-R: Steroid → ATG → Re-biopsy.
    ABMR = PIS, then R, then B: PLEX + IVIG + Steroid → Rituximab → Bortezomib.

  7. 7

    Stop 7 · Infection and follow-up

    Infection and late graft dysfunction

    Infections need less immunosuppression; late loss starts with adherence.

    BK ≥50% ↓ 10× fall by 4 wk
    1. BK nephropathy · Half, Halt, then CNI

      Antimetabolite down ≥50% → no 10-fold fall at 4 weeks: stop it, prednisone 5–10 mg/day → lower CNI (trough ~5) → re-biopsy.

      CNI-first equally acceptable (2024 BK consensus). IVIG, cidofovir, leflunomide unproven.

    2. CMV disease

      Valganciclovir 900 mg BID or IV ganciclovir 5 mg/kg q12h, GFR-adjusted; reduce antimetabolite.
      Weekly PCR; no response after 2 weeks: UL97/UL54, maribavir 400 mg BID or foscarnet.

    3. Graft pyelonephritis

      Fever, graft tenderness, pyuria: cultures, renally adjusted antibiotics, drain if obstructed.

    Over 1 year

    Adherence, trough, DSA, BK PCR, urine PCR, HbA1c, Doppler → biopsy with C4d, SV40, IF and EM.
    PTLD: mass, weight loss, high LDH → CT, tissue biopsy.

    By biopsy

    Chronic CNI toxicity: minimise CNI, never stop abruptly; mTOR inhibitor or belatacept (EBV-seropositive).
    Recurrent GN: ACE inhibitor or ARB + specific: FSGS PLEX × 9; aHUS eculizumab; MN rituximab.

    eGFR still falling: plan dialysis access and early re-listing.

    Exam trap

    Pulse steroids for SV40-positive tubulitis: that is BK; reduce immunosuppression.
    Fever with graft tenderness: graft pyelonephritis first; rejection rarely causes fever unless immunosuppression stopped.

Pocket check

Rapid recall

Order of the work-up?

Stabilise → Foley + fluids → Doppler → trough → BK/CMV PCR, DSA → biopsy.

Causes within 8 hours?

Hyperacute rejection, thrombosis, primary non-function, ischaemia-reperfusion.

Delayed graft function?

Dialysis within the first week; biopsy if beyond ~1–2 weeks.

Urine leak or lymphocele?

Fluid creatinine well above serum: leak. Like serum: lymphocele.

Biopsy safety?

Platelets >100, PT and APTT <1.2 × control, BP <140/90.

Presumptive BK nephropathy?

Plasma PCR >10,000 copies/mL: antimetabolite down at least 50%.

TCMR IA/IB?

Methylprednisolone 250–500 mg × 3–5 days; resistant: rATG.

Active ABMR?

PLEX 2–5 + IVIG 100–200 mg/kg after each, pulse steroid.

Donor unknown?

Anti-HLA antibody screen, not DSA; C4d substitutes on biopsy.

Three rules for every ladder?

Keep immunosuppression on; treat the biopsy; no response = re-biopsy, recheck trough, BK, DSA.

Next tabs: algorithms, spoken answer, viva questions.

Sources: KDIGO transplant recipients 2009; Banff 2019 and 2022; CCN 2023 ch 109; 2024 BK consensus.

8

BK virus nephropathy

Open the full topic →
Fast Recap · 6 stops

BK virus nephropathy at a glance

Driven by net immunosuppression; treated by stepwise reduction of immunosuppression, not antivirals.

  1. tac 13 Risk factors Net immunosuppression: the dominant risk.
  2. Natural history Viruria → viraemia (~4 wk) → nephropathy (~8 wk).
  3. Management Stepwise reduction; plasma PCR every 2–4 weeks.
  1. 1

    Stop 1 · Risk

    Risk factors and timing

    Four blocks; net immunosuppression first.

    peak 3–6 0 3 6 12 mo tac 13 D+/R−
    1

    Net immunosuppression

    Tacrolimus over cyclosporine, trough persistently >10 ng/mL, mycophenolate, high steroid, ATG, rejection treatment. The only modifiable block.

    2

    Recipient

    Older, male, diabetic, previous transplant, certain HLA types. D+/R−: highest-risk serologic mismatch.

    3

    Graft and procedure

    Deceased donor, donor shedding, cold ischaemia, DGF, HLA mismatch, ureteric stent/trauma, ABO-incompatible.

    4

    Timing

    Most in first 6 months, peak 3–6. Later cases occur: test any unexplained dysfunction.

    1. Viruria

      First.

    2. Viraemia

      ~4 weeks later; 10–20% in first 12 months.

    3. Nephropathy

      ~8 weeks after DNAemia; biopsy-proven ~8% (1–15%).

    Silent creatinine rise (2–24 months, median 9), unremarkable urinalysis: hence protocol screening.

    Memory hook
    13tac trough 4months 5–8typical target

    The planted clue: trough 13 at 4 months = BK driver and drug to move. Centre’s target decides.

  2. 2

    Stop 2 · Differential

    Differential diagnosis of graft dysfunction

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Plasma BK PCR
  2. Histopathology and Banff classification
  3. Reduction of immunosuppression
  4. Refractory BK viraemia and concurrent rejection
See the plans →
17

Living donor evaluation / complications

Open the full topic →
Fast Recap · 7 stops

Living donor evaluation at a glance

A healthy donor gains nothing medically. Protect them first: free consent, a fit kidney, risk counselling, lifelong follow-up. Then incompatible pairs and the recipient.

  1. A healthy donor No medical benefit; free consent first.
  2. −50% GFR ≈ −30% Compensatory hyperfiltration Half the mass, not half the GFR.
  3. Lifelong follow-up Early and late risks; annual checks.
  1. 1

    Stop 1 · Consent

    Voluntary informed consent

    Healthy person accepting risk: voluntariness is the first priority.

    advocate YES $
    • No coercion or financial incentive
    • Independent donor advocate, separate from the transplant team
    • Psychosocial evaluation: coercion, money, unaddressed psychiatric illness
    • Later adjustment problems or regret (“donor psychological syndrome”)

    Withdrawal: allowed at any stage; support it, protect confidentiality (KDIGO 2.7–2.8).

    Consent established

    Proceed to recipient diagnosis and medical work-up.

    Coercion or payment

    Halt the process; involve the independent donor advocate.

    Memory hook

    “Will before kidney.” Consent and psychosocial safety before GFR.

  2. 2

    Stop 2 · Genetics

    Hereditary recipient disease

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Donor medical evaluation
  2. Donor risks and long-term follow-up
  3. Kidney paired exchange
  4. Paired exchange versus desensitisation
  5. Transplant candidate evaluation
See the plans →
28

Delayed graft function / day-1 oliguria

Open the full topic →
Fast Recap · six stops

Delayed graft function at a glance

A quiet new kidney: exclude the fixable causes before calling it ATN, and keep immunosuppression.

  1. Fixable causes Catheter, volume, vessels: check first.
  2. Ischaemic ATN Most common cause, not the default.
  3. Rejection or CMV Atypical course: biopsy and CMV PCR.
  1. 1

    Stop 1 · Definition

    Definition and risk factors

    Defined by dialysis, not by urine volume.

    7 days HD

    Delayed graft function

    Dialysis needed within the first post-transplant week.

    About 31% of deceased-donor transplants (US centres); oliguria may be absent.

    Slow graft function

    Creatinine >3 mg/dL (~265 µmol/L) in week 1, no dialysis.

    Slow creatinine fall: not DGF.

    Risk factors

    Donor

    DCD, expanded-criteria, donor AKI, older age, female, obesity, diabetes, high creatinine, long brain death, high KDPI.

    Ischaemia

    Prolonged cold and warm ischaemia time; deceased rather than living donation.

    Recipient

    Male, African American, obesity, diabetes, previous transplant, sensitisation (PRA >50%), HLA mismatch, ABO incompatibility, longer pre-transplant dialysis, hypotension or volume contraction, early high CNI levels.

    Exam trap

    DGF ≠ slow graft function. State the definition verbatim: dialysis in week 1.

  2. 2

    Stop 2 · Bedside

    Day-1 oliguria work-up

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Doppler ultrasound and resistive index
  2. Differential diagnosis
  3. Management of established DGF
  4. Prolonged DGF and graft biopsy
See the plans →
36

Calcineurin inhibitor toxicity

Open the full topic →
Fast Recap · 6 stops

CNI toxicity at a glance

Too much drug squeezes the afferent arteriole: reversible early, scarring late. Exclude the mimics, then reduce to target.

  1. Tac High trough Months out, creatinine slowly rising.
  2. Afferent vasoconstriction Early: reversible with dose reduction.
  3. Chronic scarring Hyalinosis, stripes: partly irreversible.
  1. 1

    Stop 1 · Diagnosis

    Clinical and biochemical diagnosis

    Rising creatinine, high trough, raised resistive index.

    tac 16 µg/L 90 180 creatinine

    Target trough

    Set by time since transplant and immunologic risk.

    Classic case

    Month 4: tacrolimus 16 µg/L, creatinine 140–180 from 90. Supratherapeutic.

    Systemic clues at the same visit

    • Tremor, headache, lower seizure threshold
    • Hyperkalaemia: lower Na/K-ATPase activity and aldosterone synthesis
    • Hypomagnesaemia: urinary wasting, persists despite replacement
    • Hypertension, hyperlipidaemia, post-transplant diabetes

    Mechanism: afferent vasoconstriction from raised sympathetic tone and RAS activity.

    Ciclosporin: C0 predicts AUC poorly; C2 (within 15 min of 2 h) is better but logistically difficult.

    Exam trap

    Quoting one fixed trough number: targets depend on phase and risk.

  2. 2

    Stop 2 · Exclusion

    Differential diagnosis

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Histological diagnosis
  2. CNI-associated thrombotic microangiopathy
  3. Dose reduction to target trough
  4. Chronic and refractory toxicity
See the plans →
41

CMV infection in transplant

Open the full topic →
Fast Recap · seven stops

CMV infection in transplant at a glance

Serostatus sets the risk, net immunosuppression amplifies it. Prevent, detect by PCR, treat, genotype if it persists.

  1. D+ R− Serostatus sets the risk D+/R− highest: primary infection.
  2. ATG net IS Amplified by immunosuppression ATG, lymphodepletion, rejection treatment.
  3. weekly PCR Treat below threshold Weekly PCR; genotype if it persists.
  1. 1

    Stop 1 · Risk

    Risk stratification

    Donor and recipient serostatus decide prevention.

    D+/R− R+ D−/R−
    !

    D+/R−

    Highest: primary infection.

    R+

    R+

    Intermediate: reactivation, regardless of donor.

    −

    D−/R−

    Lowest.

    Risk amplifiers

    • ATG or lymphodepleting induction; prolonged or repeated antilymphocyte courses
    • Rejection treatment: pulse steroids, ATG
    • High net immunosuppression; older age; concurrent infections
    • Blood products from CMV-seropositive donors

    Older recipients: immunosenescence lowers rejection risk, so standard targets may over-immunosuppress.

    Exam trap

    D+/R−, not R+ or D−/R−, is the highest-risk combination.

  2. 2

    Stop 2 · Prevention

    Universal prophylaxis

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Pre-emptive therapy and surveillance
  2. Clinical presentation and diagnosis
  3. Graft dysfunction with CMV viraemia
  4. Antiviral treatment of CMV disease
  5. Refractory and resistant CMV
See the plans →
42

Commercial transplant abroad — returning with graft dysfunction

Open the full topic →
Fast Recap · 7 stops

Graft dysfunction after transplant abroad at a glance

No records, unknown donor. Save the patient, exclude the reversible, biopsy, then treat by the biopsy.

  1. ? No records Unknown donor, HLA, crossmatch, induction.
  2. Failing graft High creatinine, sometimes anuric.
  3. Biopsy decides C4d stands in for DSA.
  1. 1

    Stop 1 · Emergency

    Initial stabilisation

    Save the patient, then the graft.

    K⁺ dialyse now

    Urgent dialysis

    Hyperkalaemia, acidosis, overload, uraemia.

    Anuria with Cr 400–700 µmol/L: usually now.
    Dialysis never delays the work-up.

    Immunosuppression

    Do not stop it because records are missing.

    Check what he actually takes; tacrolimus trough today.

    History
    • Date, country, discharge papers
    • Induction; current drugs and doses; ran out?
    • Urine output since surgery; fever
    • Prior transplants, pregnancies, transfusions
    Examination
    • Volume status, temperature
    • Graft tenderness or swelling
    • Wound: collection or leak; catheter
    Exam trap

    Never refuse care or lecture on ethics in an acute case: treat first, document.

  2. 2

    Stop 2 · Differential

    Causes of early allograft dysfunction

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Diagnostic work-up
  2. Allograft biopsy
  3. T-cell-mediated rejection
  4. Antibody-mediated rejection and other lesions
  5. Monitoring and continuity of care
See the plans →
51

Transplant tourism / Declaration of Istanbul

Open the full topic →
Fast Recap · 6 stops

Transplant tourism at a glance

Counsel without judging, never facilitate the trade, treat the unwell returner as an emergency.

  1. $ Kidney bought abroad Commercial donor, unregulated centre.
  2. why? Counsel, don’t lecture Lecture him and he hides the plan.
  3. DAY 5 Returning unwell An emergency of unknown cause.
  1. 1

    Stop 1 · Approach

    Counselling approach

    Supportive, non-judgmental; understand why before discussing risk.

    related commercial

    Why patients seek transplant abroad

    1
    Waiting list

    Long deceased-donor list, prolonged dialysis.

    2
    No donor

    No suitable living-related donor locally.

    3
    Desperation

    Misinformation about “guaranteed” organs.

    4
    Brokers

    Financial incentive marketed by unregulated centres.

    Living-related donor

    Clarify the relationship first.

    Commercial or unrelated abroad

    This first branch decides the risk and the counselling.

    Memory hook

    “Listen first: a lectured patient hides the plan.”

    Exam trap

    Judging or refusing to engage: you lose the chance to keep him safe.

  2. 2

    Stop 2 · Risk counselling

    Medical, ethical and legal risks

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Safe alternatives and travel planning
  2. Early graft dysfunction: initial assessment
  3. Differential diagnosis
  4. Acute management and maintenance immunosuppression
See the plans →
52

T-cell mediated (cellular) rejection

Open the full topic →
Fast Recap · 6 stops

T-cell mediated rejection at a glance

T cells invade tubules and vessels: biopsy, grade by Banff, treat by grade.

  1. creatinine Rising creatinine Often silent; most within 3–6 months.
  2. TTTT tubulitis Biopsy and Banff grade Tubulitis + interstitial inflammation, no C4d/DSA.
  3. MP ATG grade I grade II+ Treat by grade Steroids for tubules; add ATG for arteritis.
  1. 1

    Stop 1 · Presentation

    Clinical presentation and timing

    Usually an asymptomatic creatinine rise, after week one.

    3–6 mo wk 1 peak risk rare

    Timing

    Usually after the first week; most often within 3–6 months. Rare in week one if unsensitised.

    Presentation

    Rising creatinine. Fever, graft tenderness, oliguria absent on modern immunosuppression, unless stopped.

    Triggers

    • Non-adherence
    • Subtherapeutic CNI trough
    • Under-immunosuppression (early steroid withdrawal, higher risk)
    • HLA mismatch, prior sensitisation

    Graft dysfunction by time

    Week 1
    ATN, hyperacute/accelerated rejection, obstruction or urine leak, renal artery/vein thrombosis, volume contraction.
    Under 12 weeks
    Acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrent disease.
    Over 12 weeks
    Add chronic allograft nephropathy, transplant renal artery stenosis, PTLD.
    Memory hook

    “Biopsy the creatinine rise, not the symptoms.”

  2. 2

    Stop 2 · Investigations

    Diagnostic work-up and biopsy

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Banff classification
  2. Treatment of borderline and grade I rejection
  3. Treatment of vascular rejection
  4. Monitoring and follow-up
See the plans →
60

Immunosuppression protocols / induction

Open the full topic →
Fast Recap · 7 stops

Transplant immunosuppression at a glance

Induction by risk, triple therapy at the right trough, and a staged answer when counts fall.

  1. low high Weigh the risk Low: basiliximab. High: ATG.
  2. CNI MMF steroid Triple maintenance CNI + antimetabolite + steroid.
  3. ANC Counts fall Grade the ANC, withdraw in steps.
  1. 1

    Stop 1 · Risk assessment

    Induction therapy by immunologic risk

    PRA, DSA, HLA match, re-transplant, prior rejection decide potency.

    LOW RISK HIGH RISK day 0 day 4 ATG basiliximab depleting

    Low risk

    First transplant, low PRA, no DSA, good match.
    Basiliximab (IL-2 receptor antagonist): day 0 and day 4. Minimal added infection risk.

    High risk

    Re-transplant, high PRA, DSA-positive, prior rejection.
    ATG, lymphodepleting: premedicate; watch cytokine release, leukopenia.

    Memory hook

    “The likelier the rejection, the stronger the induction.”

    Exam trap

    Basiliximab alone for a sensitised, DSA-positive or re-transplant recipient.

  2. 2

    Stop 2 · Maintenance

    Maintenance triple therapy

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Calcineurin inhibitor trough targets
  2. Adverse effects and drug interactions
  3. Post-transplant leucopenia
  4. Staged drug withdrawal
  5. PJP cover, G-CSF and recovery
See the plans →
66

Pre-transplant recipient evaluation / candidacy work-up

Open the full topic →
Fast Recap · 7 stops

Transplant recipient evaluation at a glance

An MDT asks one question: acceptable survival after transplant? Then sorts each problem: treat first, exclude, or not a reason.

  1. 6–12 months Refer early 6–12 months before dialysis.
  2. physician surgeon psycho- social MDT decides Acceptable estimated survival after transplant?
  3. do not refer delay not alone Three lists Do not refer, delay, never exclude alone.
  1. 1

    Stop 1 · Referral

    Referral and timing

    Refer early; pre-emptive living-donor transplant is preferred (1A).

    living donor 6–12 months eGFR <10
    Not on dialysis
    Refer 6–12 months before anticipated dialysis (Rec 1.1.1).
    On dialysis
    Once medically stable and failure irreversible (Rec 1.1.2).
    Pre-emptive
    Adults: eGFR <10 ml/min/1.73 m², or earlier with symptoms (1D).
    1

    Transplant physician

    2

    Transplant surgeon

    3

    Psychosocial professional

    MDT (Rec 1.2) approves when estimated survival is acceptable by national standards.

    Exam trap

    Waiting for dialysis before referral. Start the living-donor search now.

  2. 2

    Stop 2 · Candidacy

    Contraindications and deferral criteria

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Factors that do not exclude
  2. Cardiovascular and pulmonary assessment
  3. Infection and malignancy screening
  4. Immunological assessment
  5. Psychosocial, metabolic and surgical work-up
See the plans →
67

Post-transplant lymphoproliferative disease (PTLD)

Open the full topic →
Fast Recap · 6 stops

Post-transplant lymphoproliferative disorder at a glance

Immunosuppression blinds the T cells that police EBV; prove it on tissue, then climb the ladder.

  1. T cell EBV B cell Surveillance fails EBV-infected B cells proliferate.
  2. CD20 Tissue is mandatory Histology, CD20, EBER.
  3. The ladder Reduce, rituximab, R-CHOP.
  1. 1

    Stop 1 · Presentation

    Clinical presentation and differential diagnosis

    Weight loss years after transplant: malignancy until proven otherwise.

    kg cancer → infection → drug
    1. Malignancy: PTLD (commonest non-skin cancer), skin, solid cancers, Kaposi.
    2. Infection: CMV, C. difficile, norovirus, parasites, TB.
    3. Drug: mycophenolate, commonest drug cause of diarrhoea; tacrolimus, mTOR inhibitors.
    4. Graft failure with uraemic anorexia; post-transplant diabetes.

    Examine: nodes, tonsils, mouth, abdomen, liver, skin, graft, neurological screen.

    Emergencies

    GI perforation, bleeding, obstruction; sepsis; headache, seizure, confusion.

    Diarrhoea

    C. difficile: oral vancomycin 125 mg QID 10–14 days or fidaxomicin 200 mg BID 10 days. Diarrhoea raises tacrolimus levels.

    Exam trap

    Calling it mycophenolate or infection before excluding lymphoma when weight loss accompanies diarrhoea.

  2. 2

    Stop 2 · Epidemiology

    Risk factors, timing and sites

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Diagnostic work-up and staging
  2. Histological classification (WHO)
  3. Reduction of immunosuppression and rituximab
  4. Chemotherapy, refractory disease and re-transplantation
See the plans →
76

Early post-transplant surgical complications (urine leak)

Open the full topic →
Fast Recap · 6 stops

Early transplant complications at a glance

Early graft dysfunction is surgical until proven otherwise: check flow, find the collection, test the drain.

  1. Duplex first Inflow, outflow, collection, hydronephrosis.
  2. ? Perigraft collection Urinoma, lymphocele, haematoma, abscess.
  3. Cr Drain creatinine Well above serum: urine leak.
  1. 1

    Stop 1 · Emergency

    Early graft dysfunction

    Stabilise, check the Foley, duplex first, call the surgeon.

    Surgical Medical 1 2

    Surgical: exclude first

    Urine leak, ureteral obstruction, artery or vein thrombosis, TRAS, haematoma, lymphocele, wound infection.

    Medical

    ATN, prerenal (hypotension, CNI vasoconstriction), rejection, CNI toxicity, TMA, recurrent disease.

    • Haemodynamics: bleeding or sepsis?
    • Foley in place and draining; fasted
    • Serum and drain creatinine; FBC, CRP, culture
    • Tacrolimus level; no early mTOR inhibitor

    Delayed graft function: dialysis in the first 7 days; about 31% of US deceased-donor transplants; ATN is the commonest cause.

    Exam trap

    Calling oliguria “ATN” before duplex excludes leak, obstruction, thrombosis.

  2. 2

    Stop 2 · Vascular

    Vascular complications

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Perigraft fluid collections
  2. Diagnosis of urine leak
  3. Management of urine leak
  4. Ureteral obstruction and lymphocele
See the plans →
77

Suspected transplant rejection without biopsy access — empirical approach

Open the full topic →
Fast Recap · 7 stops

Rejection without biopsy at a glance

Exclude the mimics, pulse steroids as a compromise, and still get the biopsy.

  1. ? Rising creatinine Rejection is a tissue diagnosis.
  2. Exclude the mimics Volume, CNI, obstruction, BK, CMV.
  3. MP Pulse, then biopsy Empirical therapy is a compromise.
  1. 1

    Stop 1 · Principle

    Diagnostic principles

    Biopsy with DSA is the gold standard.

    DSA biopsy + DSA

    With tissue

    Names the rejection type and decides therapy.
    Endothelialitis: pathognomonic of rejection.

    Without tissue

    Empirical therapy is a compromise, not a diagnosis. Document why.

    • No non-invasive test reliably diagnoses antibody-mediated rejection.
    • Infiltrates and tubulitis: also BK, CMV, pyelonephritis, PTLD.
    • Banff IA/IB: pulse steroids. Banff IIA/IIB: T-cell-depleting antibody.
    Memory hook

    “Say compromise first, then how you will still confirm.”

  2. 2

    Stop 2 · Exclusion

    Exclusion of non-rejection causes

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. BK nephropathy and CNI toxicity
  2. Non-invasive markers
  3. Pulse corticosteroids
  4. Steroid-resistant and antibody-mediated rejection
  5. Biopsy technique and adequacy
See the plans →
98

ADPKD after transplant: rising creatinine and proteinuria

Open the full topic →
Fast Recap · 7 stops

ADPKD after transplant at a glance

ADPKD never recurs: a sick graft means a graft cause. Biopsy, then mind the native kidneys.

  1. PKD – The graft has no PKD Donor kidney: no mutation, no cysts.
  2. Cr ↑ PCR ↑ Creatinine and protein rise Think rejection, BK, CNI, GN.
  3. native kidneys Native kidneys stay Infect, bleed, raise haemoglobin.
  1. 1

    Stop 1 · Framing

    Recurrent versus de novo disease

    ADPKD is a native-kidney mutation (PKD1/PKD2).

    native graft: no cysts
    1
    ADPKD

    Cannot recur: donor kidney develops no cysts.

    2
    Recurrent

    Same native GN (IgA, FSGS, MPGN), only if one coexisted.

    3
    De novo

    New lesion (FSGS, membranous): rejection, hyperfiltration, drugs, infection.

    Exam trap

    Saying ADPKD has recurred in the graft. Proteinuria = graft problem.

  2. 2

    Stop 2 · Differential

    Differential diagnosis of allograft dysfunction

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Non-invasive investigations
  2. Allograft biopsy
  3. Treatment by biopsy diagnosis
  4. Native kidneys and nephrectomy
  5. Systemic complications
See the plans →
101

Pregnancy after kidney transplantation

Open the full topic →
Fast Recap · 6 stops

Pregnancy after kidney transplantation at a glance

Usually successful when planned: stable graft, safe drugs, close watch, and rejection told apart from pre-eclampsia.

  1. Wait for stability At least 1 year stable.
  2. Swap the teratogens MMF out, azathioprine in.
  3. Watch closely Aspirin; tacrolimus trough each visit.
  4. Deliver and breastfeed Live birth about 73–80%.
  1. 1

    Stop 1 · Planning

    Preconception criteria

    A stable graft before conception predicts success.

    Cr <125 Prot <1 g ≥12 mo stable graft
    • At least 12 months; 1–2 years practical
    • Creatinine <125 µmol/L (1.4 mg/dL)
    • Proteinuria <1 g/day
    • BP controlled (<130/80)
    • No recent rejection, no CMV viraemia
    • UTI eradicated, diabetes controlled

    Ask: time since transplant, rejection history, drugs, BP, CMV and UTI history, diabetes, planned or not.
    Contraception counselling before and after transplant. Joint renal-obstetric clinic.

    Memory hook
    1year 125µmol/L 1g/day

    Creatinine ≤1.4 mg/dL: 96% success vs 75% above it (CCN).

  2. 2

    Stop 2 · Drugs

    Immunosuppression in pregnancy

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Antenatal monitoring
  2. Maternal and fetal outcomes
  3. Pre-eclampsia versus acute rejection
  4. Delivery and postpartum care
See the plans →
102

Recurrent glomerular disease after kidney transplantation

Open the full topic →
Fast Recap · 7 stops

Recurrent glomerular disease at a glance

A new kidney treats kidney failure, not the cause. Know who recurs, prove it, block the factor.

  1. The factor returns Circulating factor, antibody or complement reaches the graft.
  2. LM IF EM Prove it on biopsy Same disease in native and graft.
  3. PE RTX ECU FSGS MN aHUS Block the factor Plasma exchange, rituximab, eculizumab.
  1. 1

    Stop 1 · Concept

    Definition and pathogenesis

    Same disease, histologically proven, in native and graft.

    death chronic recurrence 3

    Graft loss after year 1

    Third cause, behind death with function and chronic rejection.
    Time-dependent: rises with graft age.

    Size of the problem

    Up to 20% of transplants; 8.4% of graft losses at 10 years.

    • FSGS: circulating factor (CLCF1, suPAR proposed, unproven).
    • MN: anti-PLA2R. IgAN: IgA1 complexes. C3G, aHUS: complement.
    • aHUS: ischaemia-reperfusion endothelial injury triggers it early.
    • Genetic forms (podocin, nephrin): no factor, rarely recur.
    Memory hook

    “The kidney is new; the factor is not.” Transplant is still the best treatment for most.

  2. 2

    Stop 2 · Risk

    Recurrence risk by disease

    Subscribers only

Unlock the other 6 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Pre-transplant risk assessment
  2. Disease-specific timing and prevention
  3. Diagnosis of recurrence
  4. Recurrent FSGS
  5. Recurrent MN, aHUS, IgAN, C3G and lupus
See the plans →
108

Transplant immunosuppression problems: tacrolimus levels, belatacept, leukopenia

Open the full topic →
Fast Recap · 6 stops

Immunosuppression problems at a glance

Swinging tacrolimus troughs, the switch to belatacept, and a falling white count: find the cause, don’t chase numbers.

  1. Tacrolimus variability Swinging troughs predict rejection.
  2. CTLA4 -Ig Belatacept CNI-sparing; EBV-seropositive only.
  3. Leukopenia Drugs first, then CMV and parvovirus.
  1. 1

    Stop 1 · Monitoring

    Tacrolimus trough monitoring

    A valid trough first; never change dose on one value.

    12 ± 2 h whole blood
    • Whole blood, same assay.
    • 12 ± 2 h after twice-daily; 24 ± 2 h once-daily.
    • Steady state takes days: recheck no more often than alternate days.
    • Trough with food can look reassuring while AUC is low.
    Handbook
    Month 1: 10–15 · to ~6 months: 8–12 · later: 6–8 ng/mL.
    Primer
    De novo first 3 months: 5–15 · then 3–10, nearer 5.

    Centre-dependent; no trial compared ranges. Above 15 ng/mL, toxicity (especially PTDM) rises. Low haematocrit: interpret with caution (95% sits in red cells).

    Exam trap

    Rising creatinine: Doppler, DSA and biopsy, not just a dose change.

  2. 2

    Stop 2 · Diagnosis

    Intrapatient variability

    Subscribers only

Unlock the other 5 stops

Every drawing, memory hook and exam trap, the pocket check, the spoken answer, the viva questions and every section of this topic.

  1. Causes of variability and correction
  2. Belatacept
  3. Conversion from CNI to belatacept
  4. Post-transplant leukopenia
See the plans →
Home All Topics Contact Us Terms of Service Privacy Policy Refund Policy Facebook YouTube Monawib

Tools: Nephrology tools · Radiology

Disclaimer: NephroApp is an independent educational platform and is not affiliated with, endorsed by, or sponsored by any licensing authority, examination provider, or textbook publisher. The MCQ Bank provides exam-style practice for educational purposes.

Nephroapp© 2026. All rights reserved.

Made with by Dr. Hossam Abohassan